Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
Study Details
Study Description
Brief Summary
A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
Non myeloablative transplant aims to achieve the immunological advantage of graft versus tumor effect as conventional myeloablative therapy without causing high treatment related toxicities. Non myeloablative transplant has been gaining wider acceptance as a way to achieve longer disease free and over all survival in patients with low grade B-cell malignancies, which otherwise is an incurable disease. Recent studies of non-myeloablative HSCT have demonstrated the powerful effect of graft versus leukemia alone against myeloma and other malignant B-cell malignancies if the transplant is performed for low grade, low volume disease.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Non Myeloablative Treatment Non-myeloablative Transplant Conditioning Chemotherapy : Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Drug: Fludarabine
Fludarabine 30 mg/m2/day x 3 days
Radiation: Total Body Irradiation
TBI 200cGy x1 dose on transplant day
Other: Infusion of Stem Cells
On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.
|
Outcome Measures
Primary Outcome Measures
- Progressive Free Survival Post Transplant [100 days post transplant]
subjects surviving without disease progression at 100 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.
- Progressive Free Survival Post Transplant [180 days post transplant]
Subjects surviving without disease progression 180 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.
- Progressive Free Survival Post Transplant [365 days post transplant]
Subjects surviving without disease progression 365 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology.
- Progression Free Survival Post Transplant [2 years post transplant]
Subjects surviving without disease progression 2 years after transplant as evidenced by no new disease showing on radiologic scans and / or bone marrow pathology.
Secondary Outcome Measures
- Non-relapse Treatment Related Mortality [Within 100 days post transplant]
Death related to treatment without relapse within 100 days after transplant
- Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant [Post transplant up to 100 days post transplant]
Measured by number of participants that have chimerism study results that show the number of donor cells and the number of recipient cells present in the blood after post-transplant lymphocyte infusions continue to be predominately either donor or recipient.
- Composite Incidence of Acute and Chronic Graft Versus Host Disease [Up to 100 days post transplant.]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Stage II or III non-progressive disease Multiple Myeloma.
-
CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.
-
≤ 70 years old.
-
Eligible and willing HLA matched related donor.
-
Bilirubin <2xULN.
-
ALT and AST <3xULN.
-
LVEF > 40%.
-
Creatinine Clearance >40mL/min.
-
Pulmonary function DLCO corrected to ≥ 70%.
-
Minimum performance score of 70%.
-
Platelet count >130 x103 micro L.
-
LDH ≤1.5xULN.
-
No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.
-
No uncontrolled infections.
Exclusion Criteria:
-
Age >70 years old.
-
Performance status <70%.
-
Uncontrolled infections or is HIV positive
-
Prior malignancies that are felt to have a <80% probability of being cured.
-
Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.
-
Prior Allograft
-
History of rapidly growing disease at diagnosis or at any progression or have MDS.
-
No eligible and willing HLA matched donor.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama in Birmingham BMT/CT Program Outpatient Clinic | Birmingham | Alabama | United States | 35249-6979 |
Sponsors and Collaborators
- University of Alabama at Birmingham
Investigators
- Principal Investigator: William P. Vaughan, MD, University of Alabama in Birmingham
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- F080429003
- UAB-0775
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Period Title: Overall Study | |
STARTED | 5 |
COMPLETED | 3 |
NOT COMPLETED | 2 |
Baseline Characteristics
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Overall Participants | 5 |
Age (Count of Participants) | |
<=18 years |
0
0%
|
Between 18 and 65 years |
5
100%
|
>=65 years |
0
0%
|
Sex: Female, Male (Count of Participants) | |
Female |
1
20%
|
Male |
4
80%
|
Outcome Measures
Title | Progressive Free Survival Post Transplant |
---|---|
Description | subjects surviving without disease progression at 100 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology. |
Time Frame | 100 days post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 5 |
Number [participants] |
4
80%
|
Title | Non-relapse Treatment Related Mortality |
---|---|
Description | Death related to treatment without relapse within 100 days after transplant |
Time Frame | Within 100 days post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 5 |
Number [participants] |
0
0%
|
Title | Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant |
---|---|
Description | Measured by number of participants that have chimerism study results that show the number of donor cells and the number of recipient cells present in the blood after post-transplant lymphocyte infusions continue to be predominately either donor or recipient. |
Time Frame | Post transplant up to 100 days post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 5 |
Number [participant] |
1
|
Title | Composite Incidence of Acute and Chronic Graft Versus Host Disease |
---|---|
Description | |
Time Frame | Up to 100 days post transplant. |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 5 |
Number [participants] |
2
40%
|
Title | Progressive Free Survival Post Transplant |
---|---|
Description | Subjects surviving without disease progression 180 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology. |
Time Frame | 180 days post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 4 |
Number [participants] |
4
80%
|
Title | Progressive Free Survival Post Transplant |
---|---|
Description | Subjects surviving without disease progression 365 days after transplant as evidenced by decreased disease and no new disease showing on radiologic scans and / or bone marrow pathology. |
Time Frame | 365 days post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 4 |
Number [participants] |
4
80%
|
Title | Progression Free Survival Post Transplant |
---|---|
Description | Subjects surviving without disease progression 2 years after transplant as evidenced by no new disease showing on radiologic scans and / or bone marrow pathology. |
Time Frame | 2 years post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Single Arm Trial |
---|---|
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. |
Measure Participants | 4 |
Number [participants] |
2
40%
|
Adverse Events
Time Frame | ||
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Single Arm Trial | |
Arm/Group Description | Single Arm Intervention trial as noted in interventions section Fludarabine: Fludarabine 30 mg/m2/day x 3 days Total Body Irradiation: TBI 200cGy x1 dose on transplant day Infusion of Stem Cells: On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight. | |
All Cause Mortality |
||
Single Arm Trial | ||
Affected / at Risk (%) | # Events | |
Total | / (NaN) | |
Serious Adverse Events |
||
Single Arm Trial | ||
Affected / at Risk (%) | # Events | |
Total | 3/5 (60%) | |
Respiratory, thoracic and mediastinal disorders | ||
RSV pneumonia Infection | 1/5 (20%) | 1 |
Klebsiella pneumonia Infection | 1/5 (20%) | 1 |
Pneumonia | 1/5 (20%) | 1 |
Other (Not Including Serious) Adverse Events |
||
Single Arm Trial | ||
Affected / at Risk (%) | # Events | |
Total | 0/5 (0%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | William Vaughan, MD |
---|---|
Organization | UAB |
Phone | 20-934-0066 |
liwilliams@uabmc.edu |
- F080429003
- UAB-0775